Center for Immunotherapy and Cell-Based Technologies

Novosibirsk — Kaliningrad — Moscow — Irkutsk
Main

Prostate cancer

Xenovaccinotherapy for cancer

http://www.medicalnewstoday.com/rss/cancer-oncology.xmlhttp://www.medicalnewstoday.com/rss/immune_system.xmlhttp://www.medicalnewstoday.com/rss/multiple_sclerosis.xmlhttp://www.medicalnewstoday.com/rss/stem_cell_research.xml

  • docid_2.pageCache.php
  • docid_248.pageCache.php
  • docid_251.pageCache.php
  • docid_271.pageCache.php
  • docid_272.pageCache.php
  • docid_618.pageCache.php
  • docid_926.pageCache.php

30.09.2018 A systematic review of 71 studies suggests that regular aspirin intake may help treat cancers such as colon cancer, breast cancer, and prostate cancer...

16.08.2018 Age, genetics, and a poor diet are among the many risk factors for prostate cancer. By taking certain steps, a person may be able to reduce their risk...

30.07.2018 Creating a way to keep prostate cancer cells alive in the laboratory for longer leads to quicker drug trials. Sharing this widely speeds it up further...

18.06.2018 Research locates new genetic markers that may show an elevated risk of developing prostate cancer. This will help to identify men who need early scree...

06.06.2018 For the first time, a major clinical trial shows that immunotherapy can successfully treat very advanced forms of prostate cancer. ...

30.05.2018 Could a long noncoding RNA that has a role in androgen receptor signaling in prostate cancer be a treatment target that does not lead to resistance?...

14.05.2018 Women do not have a prostate in the same way as men. They do, however, have Skene glands, often called the female prostate, which have many similariti...

07.05.2018 In prostate cancer, recurring tumors become aggressive and treatment-resistant. Why does this happen, and how can it be prevented? A new study weighs ...

17.04.2018 In the largest study of its type, researchers find several new prostate cancer drug targets by harvesting and analyzing reams of genetic data....

04.04.2018 Scientists identify a class of drugs that selectively targets and kills advanced prostate cancer cells that lack the tumor-suppressor protein PTEN....


Immunotherapy for cancer

An active specific immunotherapy (vaccinotherapy) is a strategy using tumor-associated antigens for including antitumor immune responses. The small structural distinctions of the xenogenic tumor-associated antigens from their human analogues render these antigens highly immunogenic and capable of including immune-mediated, antitumor responses in a patient not only at early, but also at advanced stages of disease, when tumor-derived immunosuppression is significant. Tumor-specfic immunotherapy is able to generate a selective and long-term antitumor effect. Such a therapy has no complications attributable to chemotherapy.

Xenovaccinotherapy for cancer